TipRanks
TG Therapeutics (DE:NKB2)
FRANKFURT:NKB2
Germany Market
NKB2
TG Therapeutics
RESEARCH TOOLSreports

TG Therapeutics (NKB2) Income Statement

3 Followers

TG Therapeutics Income Statement

Last quarter (Q2 2026), TG Therapeutics's total revenue was $240.34M, an increase of 70.27% from the same quarter last year. In Q2, TG Therapeutics's net income was $7.78M. See TG Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 616.29M$ 329.00M$ 233.66M$ 2.79M$ 6.69M
Gross Profit
$ 515.57M$ 290.52M$ 219.53M$ 2.52M$ 5.90M
Operating Expenses
$ 392.25M$ 248.59M$ 198.90M$ 220.84M$ 350.67M
Depreciation and Amortization
$ 244.00K$ 280.00K$ 423.00K$ 515.00K$ 494.00K
EBITDA
$ 134.36M$ 49.90M$ 26.10M$ -213.11M$ -341.97M
Operating Income
$ 123.32M$ 41.93M$ 20.63M$ -218.32M$ -344.77M
Other Income/Expenses
$ -15.93M$ -16.34M$ -7.57M$ -5.50M$ -3.33M
Pretax Income
$ 107.39M$ 25.59M$ 13.06M$ -223.81M$ -348.10M
Net Income
$ 447.18M$ 23.38M$ 12.67M$ -223.81M$ -348.10M
Per Share Metrics
Basic EPS
$ 3.10$ 0.16$ 0.09$ -1.46$ -2.63
Diluted EPS
$ 2.77$ 0.15$ 0.09$ -1.46$ -2.63
Weighted Average Shares Outstanding
 144.32M 145.32M 141.96M 135.41M 132.22M
Weighted Average Shares Outstanding (Diluted)
 161.41M 160.34M 148.51M 135.41M 132.22M
Currency in USD

TG Therapeutics Earnings and Revenue History